Marcus E Randall1, Virginia Filiaci2, D Scott McMeekin3, Vivian von Gruenigen4, Helen Huang2, Catheryn M Yashar5, Robert S Mannel3, Jae-Weon Kim6, Ritu Salani7, Paul A DiSilvestro8, James J Burke9, Thomas Rutherford10, Nick M Spirtos11, Keith Terada12, Penny R Anderson13, Wendy R Brewster14, William Small15, Carol A Aghajanian16, David S Miller17. 1. 1 University of Kentucky, Lexington, KY. 2. 2 NRG Oncology Statistical and Data Center, Buffalo, NY. 3. 3 University of Oklahoma School of Medicine, Oklahoma City, OK. 4. 4 Summa Health System, Akron, OH. 5. 5 University of California San Diego, San Diego, CA. 6. 6 Seoul National University, Seoul, South Korea. 7. 7 Ohio State University, Columbus, OH. 8. 8 Women and Infants Hospital, Providence, RI. 9. 9 Mercer University, Savannah, GA. 10. 10 Yale University, New Haven, CT. 11. 11 Women's Cancer Center of Nevada, Las Vegas, NV. 12. 12 University of Hawaii, Honolulu, HI. 13. 13 Fox Chase Cancer Center, Philadelphia, PA. 14. 14 University of North Carolina Chapel Hill, Chapel Hill, NC. 15. 15 Loyola University, Chicago, IL. 16. 16 Memorial Sloan Kettering Cancer Center, New York, NY. 17. 17 University of Texas Southwestern Medical Center, Dallas, TX.
Abstract
PURPOSE: The primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate and high-risk early-stage endometrial carcinoma. PATIENTS AND METHODS: A randomized phase III trial was performed in eligible patients with endometrial cancer. Eligible patients had International Federation of Gynecology and Obstetrics (2009) stage I endometrioid histology with Gynecologic Oncology Group protocol 33-based high-intermediate-risk criteria, stage II disease, or stage I to II serous or clear cell tumors. Treatment was randomly assigned between RT (45 to 50.4 Gy over 5 weeks) or VCB followed by intravenous paclitaxel 175 mg/m2 (3 hours) plus carboplatin (area under the curve, 6) every 21 days for three cycles. RESULTS: The median age of the 601 patients was 63 years, and 74% had stage I disease. Histologies included endometrioid (71%), serous (15%), and clear cell (5%). With a median follow-up of 53 months, the 60-month RFS was 0.76 (95% CI, 0.70 to 0.81) for RT and 0.76 (95% CI, 0.70 to 0.81) for VCB/C (hazard ratio, 0.92; 90% confidence limit, 0.69 to 1.23). The 60-month overall survival was 0.87 (95% CI, 0.83 to 0.91) for RT and 0.85 (95% CI, 0.81 to 0.90) for VCB/C (hazard ratio, 1.04; 90% confidence limit, 0.71 to 1.52). Vaginal and distant recurrence rates were similar between arms. Pelvic or para-aortic nodal recurrences were more common with VCB/C (9% v 4%). There was no heterogeneity of treatment effect with respect to RFS or overall survival among clinical or pathologic variables evaluated. CONCLUSION: Superiority of VCB/C compared with pelvic RT was not demonstrated. Acute toxicity was greater with VCB/C; late toxicity was similar. Pelvic RT alone remains an effective, well-tolerated, and appropriate adjuvant treatment in high-risk early-stage endometrial carcinomas of all histologies.
PURPOSE: The primary objective was to determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with pelvic radiation therapy (RT) in high-intermediate and high-risk early-stage endometrial carcinoma. PATIENTS AND METHODS: A randomized phase III trial was performed in eligible patients with endometrial cancer. Eligible patients had International Federation of Gynecology and Obstetrics (2009) stage I endometrioid histology with Gynecologic Oncology Group protocol 33-based high-intermediate-risk criteria, stage II disease, or stage I to II serous or clear cell tumors. Treatment was randomly assigned between RT (45 to 50.4 Gy over 5 weeks) or VCB followed by intravenous paclitaxel 175 mg/m2 (3 hours) plus carboplatin (area under the curve, 6) every 21 days for three cycles. RESULTS: The median age of the 601 patients was 63 years, and 74% had stage I disease. Histologies included endometrioid (71%), serous (15%), and clear cell (5%). With a median follow-up of 53 months, the 60-month RFS was 0.76 (95% CI, 0.70 to 0.81) for RT and 0.76 (95% CI, 0.70 to 0.81) for VCB/C (hazard ratio, 0.92; 90% confidence limit, 0.69 to 1.23). The 60-month overall survival was 0.87 (95% CI, 0.83 to 0.91) for RT and 0.85 (95% CI, 0.81 to 0.90) for VCB/C (hazard ratio, 1.04; 90% confidence limit, 0.71 to 1.52). Vaginal and distant recurrence rates were similar between arms. Pelvic or para-aortic nodal recurrences were more common with VCB/C (9% v 4%). There was no heterogeneity of treatment effect with respect to RFS or overall survival among clinical or pathologic variables evaluated. CONCLUSION: Superiority of VCB/C compared with pelvic RT was not demonstrated. Acute toxicity was greater with VCB/C; late toxicity was similar. Pelvic RT alone remains an effective, well-tolerated, and appropriate adjuvant treatment in high-risk early-stage endometrial carcinomas of all histologies.
Authors: D Scott McMeekin; Virginia L Filiaci; J Tate Thigpen; Holly H Gallion; Gini F Fleming; William H Rodgers Journal: Gynecol Oncol Date: 2007-07 Impact factor: 5.482
Authors: Remi A Nout; Lonneke V van de Poll-Franse; Marnix L M Lybeert; Carla C Wárlám-Rodenhuis; Jan J Jobsen; Jan Willem M Mens; Ludy C H W Lutgens; Betty Pras; Wim L J van Putten; Carien L Creutzberg Journal: J Clin Oncol Date: 2011-03-28 Impact factor: 44.544
Authors: Carien L Creutzberg; Remi A Nout; Marnix L M Lybeert; Carla C Wárlám-Rodenhuis; Jan J Jobsen; Jan-Willem M Mens; Ludy C H W Lutgens; Elisabeth Pras; Lonneke V van de Poll-Franse; Wim L J van Putten Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-02 Impact factor: 7.038
Authors: Thomas Hogberg; Mauro Signorelli; Carlos Freire de Oliveira; Roldano Fossati; Andrea Alberto Lissoni; Bengt Sorbe; Håkan Andersson; Seija Grenman; Caroline Lundgren; Per Rosenberg; Karin Boman; Bengt Tholander; Giovanni Scambia; Nicholas Reed; Gennaro Cormio; Germana Tognon; Jackie Clarke; Tomasz Sawicki; Paolo Zola; Gunnar Kristensen Journal: Eur J Cancer Date: 2010-07-07 Impact factor: 9.162
Authors: C L Creutzberg; W L van Putten; P C Koper; M L Lybeert; J J Jobsen; C C Wárlám-Rodenhuis; K A De Winter; L C Lutgens; A C van den Bergh; E van de Steen-Banasik; H Beerman; M van Lent Journal: Lancet Date: 2000-04-22 Impact factor: 79.321
Authors: R A Nout; V T H B M Smit; H Putter; I M Jürgenliemk-Schulz; J J Jobsen; L C H W Lutgens; E M van der Steen-Banasik; J W M Mens; A Slot; M C Stenfert Kroese; B N F M van Bunningen; A C Ansink; W L J van Putten; C L Creutzberg Journal: Lancet Date: 2010-03-06 Impact factor: 79.321
Authors: Hadassah Goldberg; Robert C Miller; Roxolyana Abdah-Bortnyak; Mariana Steiner; Ferah Yildiz; Amichay Meirovitz; Salvador Villà; Philip M P Poortmans; David Azria; Jamal Zidan; Mahmut Ozsahin; Ufuk Abacioglu; Douglas G Gold; Amnon Amit; Ofer Lavie; I Lale Atahan; Abraham Kuten Journal: Gynecol Oncol Date: 2007-12-21 Impact factor: 5.482
Authors: Henry M Keys; James A Roberts; Virginia L Brunetto; Richard J Zaino; Nick M Spirtos; Jeffrey D Bloss; Andrew Pearlman; Mitchell A Maiman; Jeffrey G Bell Journal: Gynecol Oncol Date: 2004-03 Impact factor: 5.482
Authors: Ashley S Felix; Eric M McLaughlin; Bette J Caan; David E Cohn; Garnet L Anderson; Electra D Paskett Journal: Int J Cancer Date: 2019-10-31 Impact factor: 7.396
Authors: Koji Matsuo; Shinya Matsuzaki; David J Nusbaum; Hiroko Machida; Yoshikazu Nagase; Brendan H Grubbs; Lynda D Roman; Jason D Wright; Philipp Harter; Maximilian Klar Journal: Eur J Cancer Date: 2020-05-17 Impact factor: 9.162
Authors: Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu Journal: Virchows Arch Date: 2021-02 Impact factor: 4.064
Authors: Koji Matsuo; David J Nusbaum; Shinya Matsuzaki; Erica J Chang; Lynda D Roman; Jason D Wright; Philipp Harter; Maximilian Klar Journal: Gynecol Oncol Date: 2020-07-18 Impact factor: 5.482
Authors: Anna L Beavis; Ting-Tai Yen; Rebecca L Stone; Stephanie L Wethington; Caitlin Carr; Ji Son; Laura Chambers; Chad M Michener; Stephanie Ricci; Wesley C Burkett; Debra L Richardson; Allison-Stuart Staley; Susie Ahn; Paola A Gehrig; Diogo Torres; Sean C Dowdy; Mackenzie W Sullivan; Susan C Modesitt; Catherine Watson; Ashely Veade; Jessie Ehrisman; Laura Havrilesky; Angeles Alvarez Secord; Amy Loreen; Kaitlyn Griffin; Amanda Jackson; Akila N Viswanathan; Leah R Jager; Amanda N Fader Journal: Gynecol Oncol Date: 2020-01-14 Impact factor: 5.482